Sign inJoin waitlistJoin the waitlist

FE

Fernando Escalona

Medical Director Auxilio Mutuo Cancer Center · University of Puerto Rico School of Medicine

Credentials: · · · · ·

History

University of Puerto Rico School of Medicine
Present
Lymphoma Division · University of Puerto Rico School of Medicine
Present
Department of · University of Puerto Rico School of Medicine
Present

The University of Texas System Cancer Center
1976–1977
Two-Year Fellowship in Medical Oncology
1974–1976
University District Hospital
1973–1974
Internal Medicine
1970–1973
University of Puerto Rico School of Medicine
1966–1970
BS University of Puerto Rico (biology major) Río Piedras, PR. – 1963-1966
1962–1966

Research

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group
Review · Journal of Clinical Oncology · 1999 · 3,123 citations
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
Journal of Clinical Oncology · 1998 · 2,302 citations
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade,…
Journal of Clinical Oncology · 2002 · 894 citations

PM
Peter Mclaughlin
135 papers
Fredrick Hagemeister
125 papers
JR
Jorge Romaguera
95 papers
Maria Rodriguez
93 papers
AY
Anas Younes
72 papers
JC
James Cox
51 papers
Chul Ha
48 papers
WP
William Pugh
34 papers
Jeffrey Medeiros
33 papers
WV
William Velasquez
33 papers
Luis Fayad
27 papers · 2 as a fellow
RW
Richard Wilder
23 papers

Grants

Monitoring Therapy of Low-Grade Lymphoma by Pcr
National Cancer Institute · R01
Contact PI · $502.7K · University of Tx Md Anderson Can Ctr
1993–1998

Clinical trials

Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm
Principal investigator · Unknown · Phase 2
Auxilio Mutuo Cancer Center
2020–2021
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
Principal investigator · Terminated · Phase 3
Spectrum Pharmaceuticals, Inc
2012–2013
"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"
Principal investigator · Unknown · Phase 2
Auxilio Mutuo Cancer Center
2011–2013
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
Principal investigator · Unknown · Phase 2
Auxilio Mutuo Cancer Center
2011